Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GSK)
NYSE:GSK
Total Valuation
GlaxoSmithKline has a market cap or net worth of $95.74B. The enterprise value is $107.43B.
Market Cap$95.74B
Enterprise Value$107.43B
Share Statistics
GlaxoSmithKline has 2,039,536,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,039,536,600
Owned by Insiders―
Owned by Institutions10.49%
Financial Efficiency
GlaxoSmithKline’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 8.51%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)8.51%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee457.18K
Profits Per Employee43.00K
Employee Count68,629
Asset Turnover0.53
Inventory Turnover1.60
Valuation Ratios
The current PE Ratio of GlaxoSmithKline is 13.5. GlaxoSmithKline’s PEG ratio is -0.44.
PE Ratio13.5
PS Ratio1.76
PB Ratio4.03
Price to Fair Value4.03
Price to FCF15.42
Price to Operating Cash Flow9.32
PEG Ratio-0.44
Income Statement
In the last 12 months, GlaxoSmithKline had revenue of 31.38B and earned 2.58B in profits. Earnings per share was 1.26.
Revenue31.38B
Gross Profit22.33B
Operating Income4.02B
Pretax Income3.48B
Net Income2.58B
EBITDA6.67B
Earnings Per Share (EPS)1.26
Cash Flow
In the last 12 months, operating cash flow was 8.60B and capital expenditures -2.64B, giving a free cash flow of 5.95B billion.
Operating Cash Flow8.60B
Free Cash Flow5.95B
Free Cash Flow per Share2.92
Dividends & Yields
GlaxoSmithKline pays an annual dividend of $0.41, resulting in a dividend yield of 3.48%
Dividend Per Share$0.41
Dividend Yield3.48%
Payout Ratio37.28%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.30
52-Week Price Change45.43%
50-Day Moving Average44.52
200-Day Moving Average39.35
Relative Strength Index (RSI)61.99
Average Volume (3m)5.27M
Important Dates
GlaxoSmithKline upcoming earnings date is Feb 4, 2026, Before Open (Confirmed).
Last Earnings DateOct 29, 2025
Next Earnings DateFeb 4, 2026
Ex-Dividend DateNov 14, 2025
Financial Position
GlaxoSmithKline as a current ratio of 0.78, with Debt / Equity ratio of 109.92%
Current Ratio0.78
Quick Ratio0.52
Debt to Market Cap0.29
Net Debt to EBITDA1.99
Interest Coverage Ratio6.11
Taxes
In the past 12 months, GlaxoSmithKline has paid 526.00M in taxes.
Income Tax526.00M
Effective Tax Rate0.15
Enterprise Valuation
GlaxoSmithKline EV to EBITDA ratio is 10.26, with an EV/FCF ratio of 19.14.
EV to Sales2.18
EV to EBITDA10.26
EV to Free Cash Flow19.14
EV to Operating Cash Flow10.43
Balance Sheet
GlaxoSmithKline has $4.45B in cash and marketable securities with $23.90B in debt, giving a net cash position of -$19.45B billion.
Cash & Marketable Securities$4.45B
Total Debt$23.90B
Net Cash-$19.45B
Net Cash Per Share-$9.53
Tangible Book Value Per Share-$4.62
Margins
Gross margin is 72.37%, with operating margin of 12.82%, and net profit margin of 8.21%.
Gross Margin72.37%
Operating Margin12.82%
Pretax Margin11.08%
Net Profit Margin8.21%
EBITDA Margin21.25%
EBIT Margin13.12%
Analyst Forecast
The average price target for GlaxoSmithKline is $44.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$44.00
Price Target Upside-8.07% Downside
Analyst ConsensusHold
Analyst Count2
Revenue Growth Forecast5.97%
EPS Growth Forecast128.66%